Skip to content

Initial analysis of COVID-19 data using Galaxy, BioConda and public research infrastructures

Notifications You must be signed in to change notification settings

eosc-life/SARS-CoV-2

 
 

Folders and files

NameName
Last commit message
Last commit date

Latest commit

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Repository files navigation

sidebar editLink

Analysis of COVID-19 data using Galaxy, BioConda and public research infrastructure

DOI

Powered by: usegalaxy.org usegalaxy.eu usegalaxy.be usegalaxy.org.au

This repo serves as a companion to our study describing the analysis of early COVID-19 data. We currently feature two different projects: one analyzing the COVID-19 Genome and the other performing virtual screening on the SARS-CoV-2 main protease.

It contains descriptions of workflows and exact versions of all software used. The goals of this study were to:

  1. Underscore the importance of access to raw data
  2. Demonstrate that existing community efforts in curation and deployment of biomedical software can reliably support rapid reproducible research during global crises

The analyses have been performed using the Galaxy platform and open source tools from BioConda. Tools were run using XSEDE resources maintained by the Texas Advanced Computing Center (TACC), Pittsburgh Supercomputing Center (PSC), and Indiana University in the U.S., de.NBI and VSC cloud resources on the European side, STFC-IRIS at the Diamond Light Source, and ARDC cloud resources in Australia.

Galaxy Project   European Galaxy Project   Australian Galaxy Project   bioconda   XSEDE   TACC   de.NBI   ELIXIR   PSC   Indiana University   Galaxy Training Network   Bio Platforms Australia   Australian Research Data Commons   VIB   ELIXIR Belgium   Vlaams Supercomputer Center   EOSC-Life   Datamonkey  

About

Initial analysis of COVID-19 data using Galaxy, BioConda and public research infrastructures

Resources

Stars

Watchers

Forks

Packages

No packages published

Languages

  • Jupyter Notebook 97.7%
  • Vue 1.7%
  • Other 0.6%